HLA-E and Miyoshi myopathy: Nonetheless, our results show that the role of the NKG2A/HLA-E interaction in the success of BCG therapy, and other therapies, might differ dramatically and might be linked to the HLA-B −21M/T genotype, with MM patients having very favorable outcomes if treated with BCG, but very unfavorable outcomes when treated with other therapies.